Global Relapsed Acute Myeloid Leukemia Drug Market Research Report 2018

June 2018 | 104 pages | ID: G2DAB9EA947EN
QYResearch

Abstracts

This report studies the global Relapsed Acute Myeloid Leukemia Drug market status and forecast, categorizes the global Relapsed Acute Myeloid Leukemia Drug market size (value & volume) by key players, type, application, and region.
This report focuses on the top players in North America, Europe, Asia-Pacific, South America, and Middle East & Africa.
The global Relapsed Acute Myeloid Leukemia Drug market is valued at million US$ in 2017 and will reach million US$ by the end of 2025, growing at a CAGR of during 2018-2025.
The major manufacturers covered in this report

• 4SC AG
• AbbVie Inc.
• Actinium Pharmaceuticals, Inc.
• Agios Pharmaceuticals, Inc.
• Amgen Inc.
• Arog Pharmaceuticals, Inc.
• Array BioPharma Inc.
• Astellas Pharma Inc.
• Astex Pharmaceuticals, Inc.
• AstraZeneca Plc
• AVEO Pharmaceuticals, Inc.
• BioLineRx, Ltd.
• Boehringer Ingelheim GmbH
• Boston Biomedical, Inc.
• Bristol-Myers Squibb Company
• Calithera Biosciences, Inc.
• Celgene Corporation
• Cornerstone Pharmaceuticals, Inc.
• CTI BioPharma Corp.

Geographically, this report studies the key regions, focuses on product sales, value, market share and growth opportunity in these regions, covering

• North America
• Europe
• China
• Japan
• Southeast Asia
• India

We can also provide the customized separate regional or country-level reports, for the following regions:

• North America
• United States
• Canada
• Mexico
• Asia-Pacific
• China
• India
• Japan
• South Korea
• Australia
• Indonesia
• Singapore
• Rest of Asia-Pacific
• Europe
• Germany
• France
• UK
• Italy
• Spain
• Russia
• Rest of Europe
• Central & South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Saudi Arabia
• Turkey
• Rest of Middle East & Africa

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

• aNK Program
• AT-9283
• BI-836858
• binimetinib
• BL-8040
• Others

On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including

• Clinic
• Hospital
• Others

The study objectives of this report are:

• To analyze and study the global Relapsed Acute Myeloid Leukemia Drug sales, value, status (2013-2017) and forecast (2018-2025).
• Focuses on the key Relapsed Acute Myeloid Leukemia Drug manufacturers, to study the sales, value, market share and development plans in future.
• Focuses on the global key manufacturers, to define, describe and analyze the market competition landscape, SWOT analysis.
• To define, describe and forecast the market by type, application and region.
• To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
• To identify significant trends and factors driving or inhibiting the market growth.
• To analyze the opportunities in the market for stakeholders by identifying the high growth segments.
• To strategically analyze each submarket with respect to individual growth trend and their contribution to the market
• To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
• To strategically profile the key players and comprehensively analyze their growth strategies.

In this study, the years considered to estimate the market size of Relapsed Acute Myeloid Leukemia Drug are as follows:

• History Year: 2013-2017
• Base Year: 2017
• Estimated Year: 2018
• Forecast Year 2018 to 2025

For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Key Stakeholders
Relapsed Acute Myeloid Leukemia Drug Manufacturers
Relapsed Acute Myeloid Leukemia Drug Distributors/Traders/Wholesalers
Relapsed Acute Myeloid Leukemia Drug Subcomponent Manufacturers
Industry Association
Downstream Vendors
Available Customizations
With the given market data, QYResearch offers customizations according to the company's specific needs. The following customization options are available for the report:
Regional and country-level analysis of the Relapsed Acute Myeloid Leukemia Drug market, by end-use.
Detailed analysis and profiles of additional market players.

Contents

Global Relapsed Acute Myeloid Leukemia Drug Market Research Report 2018

1 RELAPSED ACUTE MYELOID LEUKEMIA DRUG MARKET OVERVIEW

1.1 Product Overview and Scope of Relapsed Acute Myeloid Leukemia Drug
1.2 Relapsed Acute Myeloid Leukemia Drug Segment by Type (Product Category)
  1.2.1 Global Relapsed Acute Myeloid Leukemia Drug Production and CAGR (%) Comparison by Type (Product Category)(2013-2025)
  1.2.2 Global Relapsed Acute Myeloid Leukemia Drug Production Market Share by Type (Product Category) in 2017
  1.2.3 aNK Program
  1.2.4 AT-9283
  1.2.5 BI-836858
  1.2.6 binimetinib
  1.2.7 BL-8040
  1.2.8 Others
1.3 Global Relapsed Acute Myeloid Leukemia Drug Segment by Application
  1.3.1 Relapsed Acute Myeloid Leukemia Drug Consumption (Sales) Comparison by Application (2013-2025)
  1.3.2 Clinic
  1.3.3 Hospital
  1.3.4 Others
1.4 Global Relapsed Acute Myeloid Leukemia Drug Market by Region (2013-2025)
  1.4.1 Global Relapsed Acute Myeloid Leukemia Drug Market Size (Value) and CAGR (%) Comparison by Region (2013-2025)
  1.4.2 North America Status and Prospect (2013-2025)
  1.4.3 Europe Status and Prospect (2013-2025)
  1.4.4 China Status and Prospect (2013-2025)
  1.4.5 Japan Status and Prospect (2013-2025)
  1.4.6 Southeast Asia Status and Prospect (2013-2025)
  1.4.7 India Status and Prospect (2013-2025)
1.5 Global Market Size (Value) of Relapsed Acute Myeloid Leukemia Drug (2013-2025)
  1.5.1 Global Relapsed Acute Myeloid Leukemia Drug Revenue Status and Outlook (2013-2025)
  1.5.2 Global Relapsed Acute Myeloid Leukemia Drug Capacity, Production Status and Outlook (2013-2025)

2 GLOBAL RELAPSED ACUTE MYELOID LEUKEMIA DRUG MARKET COMPETITION BY MANUFACTURERS

2.1 Global Relapsed Acute Myeloid Leukemia Drug Capacity, Production and Share by Manufacturers (2013-2018)
  2.1.1 Global Relapsed Acute Myeloid Leukemia Drug Capacity and Share by Manufacturers (2013-2018)
  2.1.2 Global Relapsed Acute Myeloid Leukemia Drug Production and Share by Manufacturers (2013-2018)
2.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue and Share by Manufacturers (2013-2018)
2.3 Global Relapsed Acute Myeloid Leukemia Drug Average Price by Manufacturers (2013-2018)
2.4 Manufacturers Relapsed Acute Myeloid Leukemia Drug Manufacturing Base Distribution, Sales Area and Product Type
2.5 Relapsed Acute Myeloid Leukemia Drug Market Competitive Situation and Trends
  2.5.1 Relapsed Acute Myeloid Leukemia Drug Market Concentration Rate
  2.5.2 Relapsed Acute Myeloid Leukemia Drug Market Share of Top 3 and Top 5 Manufacturers
  2.5.3 Mergers & Acquisitions, Expansion

3 GLOBAL RELAPSED ACUTE MYELOID LEUKEMIA DRUG CAPACITY, PRODUCTION, REVENUE (VALUE) BY REGION (2013-2018)

3.1 Global Relapsed Acute Myeloid Leukemia Drug Capacity and Market Share by Region (2013-2018)
3.2 Global Relapsed Acute Myeloid Leukemia Drug Production and Market Share by Region (2013-2018)
3.3 Global Relapsed Acute Myeloid Leukemia Drug Revenue (Value) and Market Share by Region (2013-2018)
3.4 Global Relapsed Acute Myeloid Leukemia Drug Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
3.5 North America Relapsed Acute Myeloid Leukemia Drug Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
3.6 Europe Relapsed Acute Myeloid Leukemia Drug Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
3.7 China Relapsed Acute Myeloid Leukemia Drug Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
3.8 Japan Relapsed Acute Myeloid Leukemia Drug Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
3.9 Southeast Asia Relapsed Acute Myeloid Leukemia Drug Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
3.10 India Relapsed Acute Myeloid Leukemia Drug Capacity, Production, Revenue, Price and Gross Margin (2013-2018)

4 GLOBAL RELAPSED ACUTE MYELOID LEUKEMIA DRUG SUPPLY (PRODUCTION), CONSUMPTION, EXPORT, IMPORT BY REGION (2013-2018)

4.1 Global Relapsed Acute Myeloid Leukemia Drug Consumption by Region (2013-2018)
4.2 North America Relapsed Acute Myeloid Leukemia Drug Production, Consumption, Export, Import (2013-2018)
4.3 Europe Relapsed Acute Myeloid Leukemia Drug Production, Consumption, Export, Import (2013-2018)
4.4 China Relapsed Acute Myeloid Leukemia Drug Production, Consumption, Export, Import (2013-2018)
4.5 Japan Relapsed Acute Myeloid Leukemia Drug Production, Consumption, Export, Import (2013-2018)
4.6 Southeast Asia Relapsed Acute Myeloid Leukemia Drug Production, Consumption, Export, Import (2013-2018)
4.7 India Relapsed Acute Myeloid Leukemia Drug Production, Consumption, Export, Import (2013-2018)

5 GLOBAL RELAPSED ACUTE MYELOID LEUKEMIA DRUG PRODUCTION, REVENUE (VALUE), PRICE TREND BY TYPE

5.1 Global Relapsed Acute Myeloid Leukemia Drug Production and Market Share by Type (2013-2018)
5.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue and Market Share by Type (2013-2018)
5.3 Global Relapsed Acute Myeloid Leukemia Drug Price by Type (2013-2018)
5.4 Global Relapsed Acute Myeloid Leukemia Drug Production Growth by Type (2013-2018)

6 GLOBAL RELAPSED ACUTE MYELOID LEUKEMIA DRUG MARKET ANALYSIS BY APPLICATION

6.1 Global Relapsed Acute Myeloid Leukemia Drug Consumption and Market Share by Application (2013-2018)
6.2 Global Relapsed Acute Myeloid Leukemia Drug Consumption Growth Rate by Application (2013-2018)
6.3 Market Drivers and Opportunities
  6.3.1 Potential Applications
  6.3.2 Emerging Markets/Countries

7 GLOBAL RELAPSED ACUTE MYELOID LEUKEMIA DRUG MANUFACTURERS PROFILES/ANALYSIS

7.1 4SC AG
  7.1.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
  7.1.2 Relapsed Acute Myeloid Leukemia Drug Product Category, Application and Specification
    7.1.2.1 Product A
    7.1.2.2 Product B
  7.1.3 4SC AG Relapsed Acute Myeloid Leukemia Drug Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
  7.1.4 Main Business/Business Overview
7.2 AbbVie Inc.
  7.2.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
  7.2.2 Relapsed Acute Myeloid Leukemia Drug Product Category, Application and Specification
    7.2.2.1 Product A
    7.2.2.2 Product B
  7.2.3 AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
  7.2.4 Main Business/Business Overview
7.3 Actinium Pharmaceuticals, Inc.
  7.3.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
  7.3.2 Relapsed Acute Myeloid Leukemia Drug Product Category, Application and Specification
    7.3.2.1 Product A
    7.3.2.2 Product B
  7.3.3 Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
  7.3.4 Main Business/Business Overview
7.4 Agios Pharmaceuticals, Inc.
  7.4.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
  7.4.2 Relapsed Acute Myeloid Leukemia Drug Product Category, Application and Specification
    7.4.2.1 Product A
    7.4.2.2 Product B
  7.4.3 Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
  7.4.4 Main Business/Business Overview
7.5 Amgen Inc.
  7.5.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
  7.5.2 Relapsed Acute Myeloid Leukemia Drug Product Category, Application and Specification
    7.5.2.1 Product A
    7.5.2.2 Product B
  7.5.3 Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Capacity, Production, Revenue, Price and Gross Margin (2015-2018)
  7.5.4 Main Business/Business Overview
7.6 Arog Pharmaceuticals, Inc.
  7.6.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
  7.6.2 Relapsed Acute Myeloid Leukemia Drug Product Category, Application and Specification
    7.6.2.1 Product A
    7.6.2.2 Product B
  7.6.3 Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
  7.6.4 Main Business/Business Overview
7.7 Array BioPharma Inc.
  7.7.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
  7.7.2 Relapsed Acute Myeloid Leukemia Drug Product Category, Application and Specification
    7.7.2.1 Product A
    7.7.2.2 Product B
  7.7.3 Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
  7.7.4 Main Business/Business Overview
7.8 Astellas Pharma Inc.
  7.8.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
  7.8.2 Relapsed Acute Myeloid Leukemia Drug Product Category, Application and Specification
    7.8.2.1 Product A
    7.8.2.2 Product B
  7.8.3 Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
  7.8.4 Main Business/Business Overview
7.9 Astex Pharmaceuticals, Inc.
  7.9.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
  7.9.2 Relapsed Acute Myeloid Leukemia Drug Product Category, Application and Specification
    7.9.2.1 Product A
    7.9.2.2 Product B
  7.9.3 Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
  7.9.4 Main Business/Business Overview
7.10 AstraZeneca Plc
  7.10.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
  7.10.2 Relapsed Acute Myeloid Leukemia Drug Product Category, Application and Specification
    7.10.2.1 Product A
    7.10.2.2 Product B
  7.10.3 AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Capacity, Production, Revenue, Price and Gross Margin (2013-2020)
  7.10.4 Main Business/Business Overview
7.11 AVEO Pharmaceuticals, Inc.
7.12 BioLineRx, Ltd.
7.13 Boehringer Ingelheim GmbH
7.14 Boston Biomedical, Inc.
7.15 Bristol-Myers Squibb Company
7.16 Calithera Biosciences, Inc.
7.17 Celgene Corporation
7.18 Cornerstone Pharmaceuticals, Inc.
7.19 CTI BioPharma Corp.

8 RELAPSED ACUTE MYELOID LEUKEMIA DRUG MANUFACTURING COST ANALYSIS

8.1 Relapsed Acute Myeloid Leukemia Drug Key Raw Materials Analysis
  8.1.1 Key Raw Materials
  8.1.2 Price Trend of Key Raw Materials
  8.1.3 Key Suppliers of Raw Materials
  8.1.4 Market Concentration Rate of Raw Materials
8.2 Proportion of Manufacturing Cost Structure
  8.2.1 Raw Materials
  8.2.2 Labor Cost
  8.2.3 Manufacturing Expenses
8.3 Manufacturing Process Analysis of Relapsed Acute Myeloid Leukemia Drug

9 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

9.1 Relapsed Acute Myeloid Leukemia Drug Industrial Chain Analysis
9.2 Upstream Raw Materials Sourcing
9.3 Raw Materials Sources of Relapsed Acute Myeloid Leukemia Drug Major Manufacturers in 2017
9.4 Downstream Buyers

10 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

10.1 Marketing Channel
  10.1.1 Direct Marketing
  10.1.2 Indirect Marketing
  10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
  10.2.1 Pricing Strategy
  10.2.2 Brand Strategy
  10.2.3 Target Client
10.3 Distributors/Traders List

11 MARKET EFFECT FACTORS ANALYSIS

11.1 Technology Progress/Risk
  11.1.1 Substitutes Threat
  11.1.2 Technology Progress in Related Industry
11.2 Consumer Needs/Customer Preference Change
11.3 Economic/Political Environmental Change

12 GLOBAL RELAPSED ACUTE MYELOID LEUKEMIA DRUG MARKET FORECAST (2018-2025)

12.1 Global Relapsed Acute Myeloid Leukemia Drug Capacity, Production, Revenue Forecast (2018-2025)
  12.1.1 Global Relapsed Acute Myeloid Leukemia Drug Capacity, Production and Growth Rate Forecast (2018-2025)
  12.1.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue and Growth Rate Forecast (2018-2025)
  12.1.3 Global Relapsed Acute Myeloid Leukemia Drug Price and Trend Forecast (2018-2025)
12.2 Global Relapsed Acute Myeloid Leukemia Drug Production, Consumption, Import and Export Forecast by Region (2018-2025)
  12.2.1 North America Relapsed Acute Myeloid Leukemia Drug Production, Revenue, Consumption, Export and Import Forecast (2018-2025)
  12.2.2 Europe Relapsed Acute Myeloid Leukemia Drug Production, Revenue, Consumption, Export and Import Forecast (2018-2025)
  12.2.3 China Relapsed Acute Myeloid Leukemia Drug Production, Revenue, Consumption, Export and Import Forecast (2018-2025)
  12.2.4 Japan Relapsed Acute Myeloid Leukemia Drug Production, Revenue, Consumption, Export and Import Forecast (2018-2025)
  12.2.5 Southeast Asia Relapsed Acute Myeloid Leukemia Drug Production, Revenue, Consumption, Export and Import Forecast (2018-2025)
  12.2.6 India Relapsed Acute Myeloid Leukemia Drug Production, Revenue, Consumption, Export and Import Forecast (2018-2025)
12.3 Global Relapsed Acute Myeloid Leukemia Drug Production, Revenue and Price Forecast by Type (2018-2025)
12.4 Global Relapsed Acute Myeloid Leukemia Drug Consumption Forecast by Application (2018-2025)

13 RESEARCH FINDINGS AND CONCLUSION

14 APPENDIX

14.1 Methodology/Research Approach
  14.1.1 Research Programs/Design
  14.1.2 Market Size Estimation
  14.1.3 Market Breakdown and Data Triangulation
14.2 Data Source
  14.2.1 Secondary Sources
  14.2.2 Primary Sources
14.3 Disclaimer

The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Picture of Relapsed Acute Myeloid Leukemia Drug
Figure Global Relapsed Acute Myeloid Leukemia Drug Production () and CAGR (%) Comparison by Types (Product Category) (2013-2025)
Figure Global Relapsed Acute Myeloid Leukemia Drug Production Market Share by Types (Product Category) in 2017
Figure Product Picture of aNK Program
Table Major Manufacturers of aNK Program
Figure Product Picture of AT-9283
Table Major Manufacturers of AT-9283
Figure Product Picture of BI-836858
Table Major Manufacturers of BI-836858
Figure Product Picture of binimetinib
Table Major Manufacturers of binimetinib
Figure Product Picture of BL-8040
Table Major Manufacturers of BL-8040
Figure Product Picture of Others
Table Major Manufacturers of Others
Figure Global Relapsed Acute Myeloid Leukemia Drug Consumption (K Pcs) by Applications (2013-2025)
Figure Global Relapsed Acute Myeloid Leukemia Drug Consumption Market Share by Applications in 2017
Figure Clinic Examples
Table Key Downstream Customer in Clinic
Figure Hospital Examples
Table Key Downstream Customer in Hospital
Figure Others Examples
Table Key Downstream Customer in Others
Figure Global Relapsed Acute Myeloid Leukemia Drug Market Size (Million USD), Comparison (K Pcs) and CAGR (%) by Regions (2013-2025)
Figure North America Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure Europe Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure China Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure Japan Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure Southeast Asia Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure India Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure Global Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) Status and Outlook (2013-2025)
Figure Global Relapsed Acute Myeloid Leukemia Drug Capacity, Production (K Pcs) Status and Outlook (2013-2025)
Figure Global Relapsed Acute Myeloid Leukemia Drug Major Players Product Capacity (K Pcs) (2013-2018)
Table Global Relapsed Acute Myeloid Leukemia Drug Capacity (K Pcs) of Key Manufacturers (2013-2018)
Table Global Relapsed Acute Myeloid Leukemia Drug Capacity Market Share of Key Manufacturers (2013-2018)
Figure Global Relapsed Acute Myeloid Leukemia Drug Capacity (K Pcs) of Key Manufacturers in 2017
Figure Global Relapsed Acute Myeloid Leukemia Drug Capacity (K Pcs) of Key Manufacturers in 2018
Figure Global Relapsed Acute Myeloid Leukemia Drug Major Players Product Production (K Pcs) (2013-2018)
Table Global Relapsed Acute Myeloid Leukemia Drug Production (K Pcs) of Key Manufacturers (2013-2018)
Table Global Relapsed Acute Myeloid Leukemia Drug Production Share by Manufacturers (2013-2018)
Figure 2017 Relapsed Acute Myeloid Leukemia Drug Production Share by Manufacturers
Figure 2017 Relapsed Acute Myeloid Leukemia Drug Production Share by Manufacturers
Figure Global Relapsed Acute Myeloid Leukemia Drug Major Players Product Revenue (Million USD) (2013-2018)
Table Global Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) by Manufacturers (2013-2018)
Table Global Relapsed Acute Myeloid Leukemia Drug Revenue Share by Manufacturers (2013-2018)
Table 2017 Global Relapsed Acute Myeloid Leukemia Drug Revenue Share by Manufacturers
Table 2018 Global Relapsed Acute Myeloid Leukemia Drug Revenue Share by Manufacturers
Table Global Market Relapsed Acute Myeloid Leukemia Drug Average Price (USD/Pcs) of Key Manufacturers (2013-2018)
Figure Global Market Relapsed Acute Myeloid Leukemia Drug Average Price (USD/Pcs) of Key Manufacturers in 2017
Table Manufacturers Relapsed Acute Myeloid Leukemia Drug Manufacturing Base Distribution and Sales Area
Table Manufacturers Relapsed Acute Myeloid Leukemia Drug Product Category
Figure Relapsed Acute Myeloid Leukemia Drug Market Share of Top 3 Manufacturers
Figure Relapsed Acute Myeloid Leukemia Drug Market Share of Top 5 Manufacturers
Table Global Relapsed Acute Myeloid Leukemia Drug Capacity (K Pcs) by Region (2013-2018)
Figure Global Relapsed Acute Myeloid Leukemia Drug Capacity Market Share by Region (2013-2018)
Figure Global Relapsed Acute Myeloid Leukemia Drug Capacity Market Share by Region (2013-2018)
Figure 2017 Global Relapsed Acute Myeloid Leukemia Drug Capacity Market Share by Region
Table Global Relapsed Acute Myeloid Leukemia Drug Production by Region (2013-2018)
Figure Global Relapsed Acute Myeloid Leukemia Drug Production (K Pcs) by Region (2013-2018)
Figure Global Relapsed Acute Myeloid Leukemia Drug Production Market Share by Region (2013-2018)
Figure 2017 Global Relapsed Acute Myeloid Leukemia Drug Production Market Share by Region
Table Global Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) by Region (2013-2018)
Table Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Region (2013-2018)
Figure Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Region (2013-2018)
Table 2017 Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Region
Figure Global Relapsed Acute Myeloid Leukemia Drug Capacity, Production (K Pcs) and Growth Rate (2013-2018)
Table Global Relapsed Acute Myeloid Leukemia Drug Capacity, Production (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Table North America Relapsed Acute Myeloid Leukemia Drug Capacity, Production (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Table Europe Relapsed Acute Myeloid Leukemia Drug Capacity, Production (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Table China Relapsed Acute Myeloid Leukemia Drug Capacity, Production (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Table Japan Relapsed Acute Myeloid Leukemia Drug Capacity, Production (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Table China Relapsed Acute Myeloid Leukemia Drug Capacity, Production (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Table Japan Relapsed Acute Myeloid Leukemia Drug Capacity, Production (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Table Global Relapsed Acute Myeloid Leukemia Drug Consumption (K Pcs) Market by Region (2013-2018)
Table Global Relapsed Acute Myeloid Leukemia Drug Consumption Market Share by Region (2013-2018)
Figure Global Relapsed Acute Myeloid Leukemia Drug Consumption Market Share by Region (2013-2018)
Figure 2017 Global Relapsed Acute Myeloid Leukemia Drug Consumption (K Pcs) Market Share by Region
Table North America Relapsed Acute Myeloid Leukemia Drug Production, Consumption, Import & Export (K Pcs) (2013-2018)
Table Europe Relapsed Acute Myeloid Leukemia Drug Production, Consumption, Import & Export (K Pcs) (2013-2018)
Table China Relapsed Acute Myeloid Leukemia Drug Production, Consumption, Import & Export (K Pcs) (2013-2018)
Table Japan Relapsed Acute Myeloid Leukemia Drug Production, Consumption, Import & Export (K Pcs) (2013-2018)
Table Southeast Asia Relapsed Acute Myeloid Leukemia Drug Production, Consumption, Import & Export (K Pcs) (2013-2018)
Table India Relapsed Acute Myeloid Leukemia Drug Production, Consumption, Import & Export (K Pcs) (2013-2018)
Table Global Relapsed Acute Myeloid Leukemia Drug Production (K Pcs) by Type (2013-2018)
Table Global Relapsed Acute Myeloid Leukemia Drug Production Share by Type (2013-2018)
Figure Production Market Share of Relapsed Acute Myeloid Leukemia Drug by Type (2013-2018)
Figure 2017 Production Market Share of Relapsed Acute Myeloid Leukemia Drug by Type
Table Global Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) by Type (2013-2018)
Table Global Relapsed Acute Myeloid Leukemia Drug Revenue Share by Type (2013-2018)
Figure Production Revenue Share of Relapsed Acute Myeloid Leukemia Drug by Type (2013-2018)
Figure 2017 Revenue Market Share of Relapsed Acute Myeloid Leukemia Drug by Type
Table Global Relapsed Acute Myeloid Leukemia Drug Price (USD/Pcs) by Type (2013-2018)
Figure Global Relapsed Acute Myeloid Leukemia Drug Production Growth by Type (2013-2018)
Table Global Relapsed Acute Myeloid Leukemia Drug Consumption (K Pcs) by Application (2013-2018)
Table Global Relapsed Acute Myeloid Leukemia Drug Consumption Market Share by Application (2013-2018)
Figure Global Relapsed Acute Myeloid Leukemia Drug Consumption Market Share by Applications (2013-2018)
Figure Global Relapsed Acute Myeloid Leukemia Drug Consumption Market Share by Application in 2017
Table Global Relapsed Acute Myeloid Leukemia Drug Consumption Growth Rate by Application (2013-2018)
Figure Global Relapsed Acute Myeloid Leukemia Drug Consumption Growth Rate by Application (2013-2018)
Table 4SC AG Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table 4SC AG Relapsed Acute Myeloid Leukemia Drug Capacity, Production (K Pcs), Revenue (Million USD), Price (4SC AG) and Gross Margin (2013-2018)
Figure 4SC AG Relapsed Acute Myeloid Leukemia Drug Production Growth Rate (2013-2018)
Figure 4SC AG Relapsed Acute Myeloid Leukemia Drug Production Market Share (2013-2018)
Figure 4SC AG Relapsed Acute Myeloid Leukemia Drug Revenue Market Share (2013-2018)
Table AbbVie Inc. Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Capacity, Production (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Production Growth Rate (2013-2018)
Figure AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Production Market Share (2013-2018)
Figure AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Revenue Market Share (2013-2018)
Table Actinium Pharmaceuticals, Inc. Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Capacity, Production (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Production Growth Rate (2013-2018)
Figure Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Production Market Share (2013-2018)
Figure Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Revenue Market Share (2013-2018)
Table Agios Pharmaceuticals, Inc. Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Capacity, Production (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Production Growth Rate (2013-2018)
Figure Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Production Market Share (2013-2018)
Figure Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Revenue Market Share (2013-2018)
Table Amgen Inc. Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Capacity, Production (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Production Growth Rate (2013-2018)
Figure Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Production Market Share (2013-2018)
Figure Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Revenue Market Share (2013-2018)
Table Arog Pharmaceuticals, Inc. Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Capacity, Production (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Production Growth Rate (2013-2018)
Figure Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Production Market Share (2013-2018)
Figure Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Revenue Market Share (2013-2018)
Table Array BioPharma Inc. Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Capacity, Production (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Production Growth Rate (2013-2018)
Figure Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Production Market Share (2013-2018)
Figure Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Revenue Market Share (2013-2018)
Table Astellas Pharma Inc. Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Capacity, Production (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Production Growth Rate (2013-2018)
Figure Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Production Market Share (2013-2018)
Figure Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Revenue Market Share (2013-2018)
Table Astex Pharmaceuticals, Inc. Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Capacity, Production (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Production Growth Rate (2013-2018)
Figure Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Production Market Share (2013-2018)
Figure Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Revenue Market Share (2013-2018)
Table AstraZeneca Plc Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Capacity, Production (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Production Growth Rate (2013-2018)
Figure AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Production Market Share (2013-2018)
Figure AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Revenue Market Share (2013-2018)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Relapsed Acute Myeloid Leukemia Drug
Figure Manufacturing Process Analysis of Relapsed Acute Myeloid Leukemia Drug
Figure Relapsed Acute Myeloid Leukemia Drug Industrial Chain Analysis
Table Raw Materials Sources of Relapsed Acute Myeloid Leukemia Drug Major Manufacturers in 2017
Table Major Buyers of Relapsed Acute Myeloid Leukemia Drug
Table Distributors/Traders List
Figure Global Relapsed Acute Myeloid Leukemia Drug Capacity, Production (K Pcs) and Growth Rate Forecast (2018-2025)
Figure Global Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate Forecast (2018-2025)
Figure Global Relapsed Acute Myeloid Leukemia Drug Price (Million USD) and Trend Forecast (2018-2025)
Table Global Relapsed Acute Myeloid Leukemia Drug Production (K Pcs) Forecast by Region (2018-2025)
Figure Global Relapsed Acute Myeloid Leukemia Drug Production Market Share Forecast by Region (2018-2025)
Table Global Relapsed Acute Myeloid Leukemia Drug Consumption (K Pcs) Forecast by Region (2018-2025)
Figure Global Relapsed Acute Myeloid Leukemia Drug Consumption Market Share Forecast by Region (2018-2025)
Figure North America Relapsed Acute Myeloid Leukemia Drug Production (K Pcs) and Growth Rate Forecast (2018-2025)
Figure North America Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate Forecast (2018-2025)
Table North America Relapsed Acute Myeloid Leukemia Drug Production, Consumption, Export and Import (K Pcs) Forecast (2018-2025)
Figure Europe Relapsed Acute Myeloid Leukemia Drug Production (K Pcs) and Growth Rate Forecast (2018-2025)
Figure Europe Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate Forecast (2018-2025)
Table Europe Relapsed Acute Myeloid Leukemia Drug Production, Consumption, Export and Import (K Pcs) Forecast (2018-2025)
Figure China Relapsed Acute Myeloid Leukemia Drug Production (K Pcs) and Growth Rate Forecast (2018-2025)
Figure China Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate Forecast (2018-2025)
Table China Relapsed Acute Myeloid Leukemia Drug Production, Consumption, Export and Import (K Pcs) Forecast (2018-2025)
Figure Japan Relapsed Acute Myeloid Leukemia Drug Production (K Pcs) and Growth Rate Forecast (2018-2025)
Figure Japan Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate Forecast (2018-2025)
Table Japan Relapsed Acute Myeloid Leukemia Drug Production, Consumption, Export and Import (K Pcs) Forecast (2018-2025)
Figure Southeast Asia Relapsed Acute Myeloid Leukemia Drug Production (K Pcs) and Growth Rate Forecast (2018-2025)
Figure Southeast Asia Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate Forecast (2018-2025)
Table Southeast Asia Relapsed Acute Myeloid Leukemia Drug Production, Consumption, Export and Import (K Pcs) Forecast (2018-2025)
Figure India Relapsed Acute Myeloid Leukemia Drug Production (K Pcs) and Growth Rate Forecast (2018-2025)
Figure India Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) and Growth Rate Forecast (2018-2025)
Table India Relapsed Acute Myeloid Leukemia Drug Production, Consumption, Export and Import (K Pcs) Forecast (2018-2025)
Table Global Relapsed Acute Myeloid Leukemia Drug Production (K Pcs) Forecast by Type (2018-2025)
Figure Global Relapsed Acute Myeloid Leukemia Drug Production (K Pcs) Forecast by Type (2018-2025)
Table Global Relapsed Acute Myeloid Leukemia Drug Revenue (Million USD) Forecast by Type (2018-2025)
Figure Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share Forecast by Type (2018-2025)
Table Global Relapsed Acute Myeloid Leukemia Drug Price Forecast by Type (2018-2025)
Table Global Relapsed Acute Myeloid Leukemia Drug Consumption (K Pcs) Forecast by Application (2018-2025)
Figure Global Relapsed Acute Myeloid Leukemia Drug Consumption (K Pcs) Forecast by Application (2018-2025)
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Source